If left unchecked, the power of PBMs and their complex relationships within the American healthcare system could lead to higher drug costs and diminished returns.

The pharmaceutical industry relies heavily on advanced pharmaceutical machinery to ensure the highest standards of safety, ...

Artificial intelligence continues stirring things up in chemistry. To wit: YC-backed Cambridge, U.K.-based ReactWise is using ...

The U.S. Food and Drug Administration has reportedly targeted a manufacturer of poppers, an inhalant drug that has gained ...

Policymakers at the federal and state level have considered a number of reforms, many of which have bipartisan support, to ...

In today's Pharmalittle roundup, we're reading about Medicare negotiations, U.K. drug rebates rising, and more.

Generic drugmakers and hospital pharmacists warn that added financial pressure from tariffs could strain the nation's generic drug supplies.

Seeking more efficient drug development, pharmaceutical giants and startups are encouraging AI fluency and in some cases ...

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...